Market Exclusive

SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Other Events

SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI) Files An 8-K Other Events
Item 8.01Other Events.

On December 19, 2018, Spectrum Pharmaceuticals, Inc. issued a press release announcing that, based on a subset of data from MD Anderson’s ongoing Phase 2 study, the U.S. Food and Drug Administration (FDA) did not grant Breakthrough Therapy Designation (BTD) to poziotinib for the treatment of patients with metastatic non-small cell lung cancer (NSCLC) whose tumors have EGFR exon 20 mutations. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 9.01Financial Statements and Exhibits.

(d) Exhibits.

Exhibit No.

Description

99.1

Press Release dated December 19, 2018

SPECTRUM PHARMACEUTICALS INC Exhibit
EX-99.1 2 exhibit9912018-12×19.htm EXHIBIT 99.1 Exhibit COMPANY CONTACTShiv KapoorVice President,…
To view the full exhibit click here

About SPECTRUM PHARMACEUTICALS, INC. (NASDAQ:SPPI)

Spectrum Pharmaceuticals, Inc. is a biotechnology company. The Company operates through developing and commercializing oncology and hematology drug products segment. It has approximately six approved oncology/hematology products that target different types of non-Hodgkin’s lymphoma (NHL), metastatic colorectal cancer, acute lymphoblastic leukemia (ALL) and multiple myeloma (MM). It also has two drugs in late-stage development: SPI-2012, which is being developed for chemotherapy-induced neutropenia in patients with breast cancer, and EOQUIN, which is being developed for immediate intravesical instillation post-transurethral resection of bladder tumors in patients with non-muscle invasive bladder cancer. It has a product portfolio consisting of both commercial-stage and development-stage products that address various cancer types. Its commercialized products include FUSILEV, FOLOTYN, ZEVALIN, MARQIBO, BELEODAQ and EVOMELA. Its other products include SPI-2012, POZIOTINIB and EOQUIN.

Exit mobile version